Immunolocalization of blocked and unblocked GP IIb-IIIa complexes in platelets during antithrombotic therapy with c7E3 Fab (ReoPro, abciximab)

被引：0
|
作者：
Nurden, A
Poujol, C
DurrieuJais, C
Besse, P
Jordan, R
Wagner, C
Nurden, P
机构：
[1] HOP CARDIOL,UMR 5533 CNRS,UNITE SOINS INTENS,IFR 4,PESSAC,FRANCE
[2] CENTOCOR LTD,MALVERN,PA
来源：
ATHEROSCLEROSIS | 1997年 / 134卷 / 1-2期
关键词：
D O I：
10.1016/S0021-9150(97)88959-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：184 / 184
页数：1
相关论文
共 41 条
  • [31] The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, αMβ2)
    Schwarz, M
    Nordt, T
    Bode, C
    Peter, K
    THROMBOSIS RESEARCH, 2002, 107 (3-4) : 121 - 128
  • [32] Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA)
    Zahn, R
    Haubelt, H
    Bechtloff, S
    Schneider, S
    Frilling, B
    Rustige, J
    Marsalek, P
    Seidl, K
    Senges, J
    Hellstern, P
    HERZ, 2003, 28 (05) : 445 - 452
  • [33] Clinical benefit within patient subgroups receiving c7E3 Fab (Abciximab) during percutaneous coronary revascularization: Subgroup analysis from the EPIC trial
    Aguirre, FV
    Topol, EJ
    Anderson, KM
    Kleiman, NS
    Weisman, HE
    FitzPatrick, SE
    Califf, RM
    JOURNAL OF INVASIVE CARDIOLOGY, 1996, 8 : B21 - B29
  • [34] Antithrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of coronary artery thrombosis
    Shetler, TJ
    Crowe, VG
    Bailey, BD
    Jackson, CV
    CIRCULATION, 1996, 94 (07) : 1719 - 1725
  • [35] Glycoprotein IIb/IIIa receptor antagonist c7E3 fab and anticoagulants show an additive effect on thrombin-induced platelet aggregation after high coagulant challenge in vitro
    Köstenberger, M
    Gallistl, S
    Cvirn, G
    Roschitz, B
    Muntean, W
    30TH HEMOPHILIA SYMPOSIUM, 2001, : 369 - 377
  • [36] PLATELET GLYCOPROTEIN IIB/IIIA MONOCLONAL-ANTIBODY (C7E3) REDUCES DISTAL EMBOLIZATION DURING PERCUTANEOUS INTERVENTION OF SAPHENOUS-VEIN GRAFTS
    CHALLAPALLI, RM
    EISENBERG, MJ
    SIGMON, K
    LEMBERGER, J
    CIRCULATION, 1995, 92 (08) : 2908 - 2908
  • [37] Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy
    Tselepis, AD
    Goudevenos, JA
    Tambaki, AP
    Michalis, L
    Stroumbis, CS
    Tsoukatos, DC
    Elisaf, M
    Sideris, DA
    CARDIOVASCULAR RESEARCH, 1999, 43 (01) : 183 - 191
  • [38] SHEAR-INDUCED PLATELET-AGGREGATION IS INHIBITED BY IN-VIVO INFUSION OF AN ANTI-GLYCOPROTEIN IIB/IIIA ANTIBODY FRAGMENT, C7E3 FAB, IN PATIENTS UNDERGOING CORONARY ANGIOPLASTY
    KONSTANTOPOULOS, K
    KAMAT, SG
    SCHAFER, AI
    BANEZ, EI
    JORDAN, R
    KLEIMAN, NS
    HELLUMS, JD
    CIRCULATION, 1995, 91 (05) : 1427 - 1431
  • [39] C7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-adsorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor - Results from patients with acute myocardial infarction and healthy controls
    Reininger, AJ
    Agneskirchner, J
    Bode, PA
    Spannagl, M
    Wurzinger, LJ
    THROMBOSIS AND HAEMOSTASIS, 2000, 83 (02) : 217 - 223
  • [40] Trafficking of c7E3 Fab within the different membrane systems of human platelets including those of the surface-connected canalicular system (SCCS) and alpha-granules during anti-thrombotic therapy
    Nurden, P
    Poujol, C
    Bihour, C
    Macchi, L
    Winckler, J
    Paponneau, A
    DurrieuJais, C
    Besse, P
    Wagner, C
    Jordan, R
    Nurden, A
    THROMBOSIS AND HAEMOSTASIS, 1997, : P2695 - P2695
12345